NCT05052957 2025-11-21
hSTAR GBM
Case Comprehensive Cancer Center
Phase 2 Recruiting
Clinical Trials
9 trialsNCT00275002 2022-02-11
O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00436436 2017-03-28
O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00005081 2014-08-21
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
Duke University
Phase 2 Completed
NCT00362921 2014-07-10
Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme
Duke University
Phase 2 Completed
NCT00005066 2013-09-05
O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma
University of Chicago
Phase 2 Completed
NCT00005961 2013-02-11
O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00389090 2012-02-09
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
Keryx / AOI Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00004072 2010-06-11
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
Case Comprehensive Cancer Center
Phase 2 Completed